Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Scheinert, K. Schulte, T. Zeller, J. Lammer, G. Tepe (2015)
Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC ExcipientJournal of Endovascular Therapy, 22
G. Tepe, T. Zeller, T. Albrecht, S. Heller, U. Schwarzwälder, J. Beregi, C. Claussen, A. Oldenburg, B. Scheller, U. Speck (2008)
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.The New England journal of medicine, 358 7
Henrik Schroeder, M. Werner, D. Meyer, P. Reimer, Karsten Krüger, M. Jaff, M. Brodmann (2017)
Low-Dose Paclitaxel–Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery DiseaseCirculation, 135
Xin Jia, Jiwei Zhang, B. Zhuang, W. Fu, Dan-ming Wu, Feng Wang, Yu Zhao, P. Guo, W. Bi, Shenming Wang, W. Guo (2016)
Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.JACC. Cardiovascular interventions, 9 18
D Scheinert, KL Schulte, T Zeller, J Lammer, G Tepe (2015)
Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trialJ Endovasc Ther, 22
Adam Salisbury, Haiyan Li, Katherine Vilain, M. Jaff, P. Schneider, J. Laird, D. Cohen (2016)
Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.JACC. Cardiovascular interventions, 9 22
H Schroeder, M Werner, DR Meyer (2017)
ILLUMENATE EU RCT investigators. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon)Circulation, 135
M. Herten, G. Torsello, E. Schönefeld, S. Stahlhoff (2016)
Critical appraisal of paclitaxel balloon angioplasty for femoral–popliteal arterial diseaseVascular Health and Risk Management, 12
M. Werk, T. Albrecht, D. Meyer, Mohammed Ahmed, Andrea Behne, U. Dietz, Götz Eschenbach, Holger Hartmann, Christian Lange, B. Schnorr, H. Stiepani, G. Zoccai, E. Hänninen (2012)
Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER TrialCirculation: Cardiovascular Interventions, 5
K. Katsanos, S. Spiliopoulos, I. Paraskevopoulos, A. Diamantopoulos, D. Karnabatidis (2016)
Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal ArteriesJournal of Endovascular Therapy, 23
R. Byrne, M. Joner, F. Alfonso, A. Kastrati (2014)
Drug-coated balloon therapy in coronary and peripheral artery diseaseNature Reviews Cardiology, 11
P. Krishnan, P. Faries, Khusrow Niazi, Ash Jain, R. Sachar, W. Bachinsky, Joseph Cardenas, M. Werner, M. Brodmann, J. Mustapha, C. Mena-Hurtado, M. Jaff, A. Holden, S. Lyden, M. Mewissen, B. Katzen, A. Nanjundappa, Matheen Khuddus, J. Ricci, D. Fry, M. Shishehbor, Christopher Bosarge, Richard Kovach, M. Goodwin, Mohammad Raja, Guy Mayeda, J. Sandhu, O. Rosales, W. Crowder, D. Paolini, J. Henretta, Pratik Desai, Naim Farhat, Edward Kang, G. Ansel, Mohammad Ghani, W. Miller, C. Pollock, E. Korngold, J. Angle, G. Schultz, T. Gensler, Louis Lopez, James Park, G. Al-Khoury, Charles Joels, C. Metzger (2017)
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal DiseaseCirculation, 136
(2014)
nomic analysis of endovascular interventions for femoropopliteal arterial disease : a systematic review and budget impact model for the United States and Germany
N. Diehm, C. Diehm, C. Kalka, F. Dick (2008)
Peripheral Endovascular Revascularization Trials: High Noon for Uniform Reporting StandardsActa Chirurgica Belgica, 108
D. Scheinert, S. Duda, T. Zeller, H. Krankenberg, J. Ricke, M. Bosiers, G. Tepe, Scott Naisbitt, K. Rosenfield (2014)
The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.JACC. Cardiovascular interventions, 7 1
G. Tepe, Ö. Gögebakan, U. Redlich, J. Tautenhahn, J. Ricke, Z. Halloul, D. Meyer, M. Waliszewski, B. Schnorr, T. Zeller, S. Müller-Hülsbeck, I. Ott, T. Albrecht (2017)
Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon CatheterCardioVascular and Interventional Radiology, 40
K. Rosenfield, M. Jaff, C. White, K. Rocha-Singh, C. Mena-Hurtado, D. Metzger, M. Brodmann, E. Pilger, T. Zeller, P. Krishnan, R. Gammon, S. Müller-Hülsbeck, M. Nehler, J. Benenati, D. Scheinert (2015)
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.The New England journal of medicine, 373 2
M. Werk, S. Langner, Bianka Reinkensmeier, Hans-Frank Boettcher, G. Tepe, U. Dietz, N. Hosten, B. Hamm, U. Speck, J. Ricke (2008)
Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot TrialCirculation, 118
JR Laird, PA Schneider, G Tepe (2015)
IN.PACT SFA trial investigators. Durability of Treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFAJ Am Coll Cardiol, 66
P Krishnan, P Faries, K Niazi (2017)
Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studiesCirculation, 136
K Katsanos, S Spiliopoulos, I Paraskevopoulos, A Diamantopoulos, D Karnabatidis (2016)
Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailabilityJ Endovasc Ther, 23
K Rosenfield, MR Jaff, CJ White (2015)
LEVANT 2 investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery diseaseN Engl J Med, 373
(2017)
Clinical and economic benefits of SeQuent Please OTW: Masters Thesis. Welsh School of Pharmacy, Cardiff University in collaboration with Hochschule Fresenius
J. Laird, P. Schneider, G. Tepe, M. Brodmann, T. Zeller, C. Metzger, P. Krishnan, D. Scheinert, A. Micari, D. Cohen, Hong Wang, Melissa Hasenbank, M. Jaff (2015)
Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.Journal of the American College of Cardiology, 66 21
Henrik Schroeder, D. Meyer, B. Lux, F. Ruecker, M. Martorana, S. Duda (2015)
Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first‐in‐human studyCatheterization and Cardiovascular Interventions, 86
J. Pietzsch, B. Geisler, A. Garner, T. Zeller, M. Jaff (2014)
Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and GermanyCatheterization and Cardiovascular Interventions, 84
Cardiovasc Intervent Radiol (2018) 41:1008–1014 https://doi.org/10.1007/s00270-018-1940-1 CLINICAL INVESTIGATION ARTERIAL INTERVENTIONS Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound? 1 2,3 4,5 6 • • • • Thomas Albrecht Matthias Waliszewski Catherine Roca Ulf Redlich 6 7 8 1 • • • • Jo ¨ rg Tautenhahn Maciej Pech Zuhir Halloul Ozlem Go ¨ gebakan 9 10 11 12 • • • • Dirk-Roelfs Meyer Ines Gemeinhardt Thomas Zeller Stefan Mu ¨ ller-Hu ¨ lsbeck 13 14 Ilka Ott Gunnar Tepe Received: 27 January 2018 / Accepted: 17 March 2018 / Published online: 27 March 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018 Abstract events, a cost-benefit analysis was conducted for the Ger- Purpose The previously reported 6-month angiographic man DRG system. and 12-month clinical outcomes of the CONSEQUENT Results There were no additional TLRs in both groups trial demonstrated the safety and efficacy of a novel between 14 and 24 months so that the corresponding rates paclitaxel–resveratrol-coated balloon for the treatment of remained significantly different between the treatment lesions in the femoropopliteal segment. The purpose
CardioVascular and Interventional Radiology – Springer Journals
Published: Mar 27, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.